SUITPlus Protocol Description v4.0

SUITplus
Sysmex Universal Interface

Extended IPU
Document Information
Status Release version

Version 4.0
Last edited date 20-06-2014
Issued by: Product Management
Version History
Version Date Author Comment
1.0 21-12-2011 Olivier Released version
Kaulmann
2.0 22-05-2012 Olivier 1. Adaptation of the chapter 1: Introduction
Kaulmann
2. Adaptation of the chapter 2.1.5: Restricted message codes:
Deletion of "ETB" from the table "Restricted message codes".
SUITplus is not limited on the string length. "ETB" is not use with
SUITplus.
3. Adaptation of chapter 3.5: Test result record:

• OBX-6: add a footnote for the “result comment”
• OBX-16: add a footnote for
“AnalyzerTypeÎnstrumentId^Rack^Tube”
4. Adaptation of chapter 3.6: Comment record

• C-3: add footnote for the "source" and "type"
5. Adaptation of chapter 4.1: Information concerning the
graphic-files management:
• Re-naming of the graph file names:
WBC_B ASO → WBC_BASO
SCAT_WDF → WDF
SCAT_WNR → WNR
SCAT_WPC → WPC
SCAT_RET → RET
SCAT_PLT-F → PLT_F
SCAT_RET-E → RET_EXT
DIST_WFS(FSC) → WDF_FSC
DIST_RBC(FSC) → RBC_FSC
DIST_RBC → RBC
DIST_PLT → PLT
• Adding:
WDF_EXT_BF
• Deleting:
SCAT_WDF-E
June 2014 - Version 4.0
6. Adaptation of the chapter 4.2: Adding some log file

examples
2 SUITplus interface description

Version History
7. Adaptation of the chapter 4.3.1.1:
• Change the parameter name of MCV, MCH, MCHC, IPF
• Adding HBA1C, ESR profile
8. Adaptation of chapter 4.3.2: Urinalysis section
9. Adaptation of Appendix D: IP-Flags
• WBC_Abn_Scattergramm available for XE-2100
• IG_Present available for XT1800i
10. Add the chapter 4.6 Appendix F: 
Main differences between SUITplus & SUIT
3.0 02-10-2012 Olivier 1. Adaptation of the chapter 3.6: Comment Record.
Kaulmann • The following new comment "Source" definitions were added:
B-THAL This comment belongs to B-Thalassemia analysis
COAGULATION This comment belongs to Coagulation analysis
PATIENT This comment belongs to Patient comment
SAMPLE This comment belongs to Sample comment
INFO This comment belongs to Rule information
URINE This comment belongs to Urine rule
URINALYSIS This comment belongs to UF analysis
HEMATOLOGY This comment belongs to Hemtology analysis
DIPSTICK This comment belongs to Dipstick analysis
SP This comment belongs to SP analysis
• The following new comment "Type" definition was added:
COMMENT This is a general comment type for the source
2. Adaptation of the chapter 4.2.4 Result from Extended IPU to
LIS with graph info. A new log file example was added.
3. Adaptation of the chapter 4.3.1.1 Diagnostic parameter. The
parameter code for bodyfluid "TC-BF" was renamed into
"TC-BF#".
4. Adaptation of the chapter 4.3.1.2 Research parameter. The
following new research parameters were added: "TC-
PMN%", TC-MN%", "TC-EO%"and TC-HF%"
5. Adaptation of the chapter 4.4.1 Action & Error Messages
and positive flagging information. The action & error
messages for the XN-Series were added.
6. Adaptation of the chapter 4.6 Main differences between
SUITplus and SUIT.
• point 4.e: "MN" was replaced by "A1000"
• point 5: the table was updated
SUITplus interface description 3

Version History
4.0 20.06.14 Olivier 1. Adaptation of chapter 3.3 Patient Record Field Code P-19,
Kaulmann HOST from SUIT is changed from "Y" into "N"
2. Adaptation of the chapter 3.6 Comment Record
• Delete the comment SOURCE definition: B-THAL
• Add the comment SOURCE definition: VALIDATION
3. Adaptation of chapter 4.3.1.4 Manual Differential parameter
Adding Sysmex DI-60
4. Adaptation of the chapter 4.3.2 Urinalysis section
The following parameters were added:
• RBC-U-BF
• WBC-U-BF
• TNC-U-BF
5. Adaptation of Appendix D chapter 4.4: Interpretation-Flags
(IP Flags)
Rename "Blast/Abn Lympho?" → "Blasts/Abn_Lympho?"
6. Adaptation of Appendix D chapter 4.4.1 Action & Error
Messages and positive flagging information
Add the action massage:
• "ACTION_MESSAGE_PLT"
• "ACTION_MESSAGE_Sample_Mixing_Failure?"
Re-naming following action message:
• Action_Message_RET → ACTION_MESSAGE_RET
• Action_Message_NRBC → ACTION_MESSAGE_NRBC
• Action_Message_Delta → ACTION_MESSAGE_Delta
• Action_Message_DIFF → ACTION_MESSAGE_DIFF
• Action_Message_WBC → ACTION_MESSAGE_WBC
• Action_Message_RBC → ACTION_MESSAGE_RBC
• Action_Message_Delta_WBC → ACTION_MESSAGE_Delta_WBC
• Action_Message_Delta_HGB → ACTION_MESSAGE_Delta_HGB
• Action_Message_Delta_MCV → ACTION_MESSAGE_Delta_MCV
• Action_Message_Delta_PLT → ACTION_MESSAGE_Delta_PLT
7. Adaptation of Appendix E: Additional information for LIS
Adding the chapter 4.5.3 Info about Comment management

Table of contents
1 Introduction....................................................................7
2 SUIT Interface ................................................................8

2.1 Data Link Level........................................................................................ 8
2.1.1 Setting Status .......................................................................................... 8
2.1.2 Forwarding Status ................................................................................. 10
2.1.3 End Status ............................................................................................. 10
2.1.4 Timeouts................................................................................................ 11
2.1.5 Restricted message codes .................................................................... 11
2.2 Protocol ................................................................................................. 12
2.2.1 Orders.................................................................................................... 12
2.2.2 Results................................................................................................... 13
3 Message Format ..........................................................15

3.1 Message and Record ............................................................................ 15
3.2 Header Record ...................................................................................... 16
3.3 Patient Record....................................................................................... 17
3.4 Order Record......................................................................................... 19
3.5 Test Result Record................................................................................ 22
3.6 Comment Record .................................................................................. 24
3.7 Order Inquiry Record ............................................................................. 26
3.8 Scientific Information Record................................................................. 27
3.9 End Mark Record................................................................................... 28
4 Appendixes ..................................................................29
4.1 Appendix A: Information concerning the graphic-files management ..... 29
4.2 Appendix B: Examples of Logfiles ......................................................... 30
4.2.1 Query from Extended IPU to LIS: .......................................................... 30
4.2.2 Order from LIS to Extended IPU when order exists: ............................. 30
4.2.3 Reply from LIS to Extended IPU when no order exists: ........................ 30
4.2.4 Result from Extended IPU to LIS with graph info .................................. 31
4.2.5 Quality Control log files.......................................................................... 34
4.3 Appendix C: Host codes ........................................................................ 38
4.3.1 Haematology discipline.......................................................................... 38
4.3.1.1 Diagnostic parameter ................................................................ 38
4.3.1.2 Research parameter.................................................................. 40
4.3.1.3 Services parameter ................................................................... 43
4.3.1.4 Manual Differential parameter (diagnostic parameters) ............ 45

4.3.1.5 Body Fluid Differential (diagnostic parameters)......................... 48
4.3.2 Urinalysis section .................................................................................. 49
4.3.3 Coagulation section .............................................................................. 51

4.4 Appendix D: Interpretation-Flags (IP Flags) .......................................... 52
4.4.1 Action & Error Messages and positive flagging information .................. 53
4.5 Appendix E: Additional information for LIS ............................................ 54
4.5.1 Info about a microscopically differential................................................. 54
4.5.2 Info about sorting information ................................................................ 54
4.5.3 Info about Comment management ........................................................ 55
4.6 Appendix F: Main differences between SUITplus and SUIT.................. 56

Introduction
1 Introduction
This document describes the Communication Specifications of
the enhanced Sysmex Universal Interface SUITplus.
SUITplus is only available with the Extended IPU solution.
This protocol is oriented on ASTM standards E1238-94 and

E1381-91. However, improvements were made which are not
conforming to ASTM standards.
3 Note:
SUITplus supports a 1-Line or a 2-Line connection to LIS.
When using a 1-Line connection the orders, results and
queries will be done on the same channel.
When using a 2-Line connection the orders and queries
will be done at one channel, the results will be sent at the
other channel. Generally a 2-Line connection is preferred.
When doing queries to LIS a 2-Line connection it is even
mandatory.
The connection to LIS has to be established by using a

network connection (TCP/IP). Connection parameters
have to be agreed between the Sysmex deployment staff
and LIS company where Extended IPU will be connected.

SUIT Interface
2 SUIT Interface
2.1 Data Link Level

Data Link Level consists of the following 3 types of
communication status:
 Setting Status:
Establish a logical communication and determine the
sending direction of information. This defines the Sending
and Receiving sides.
 Forwarding Status:
The Sending side transmits messages to the Receiving
side.
 End Status:
Open the communication line(s) and change to idle status
for both the Sending and Receiving side.
2.1.1 Setting Status
Establish a logical communication line to determine the

sending direction of information.
1. The Sending side transmits [ENQ] to the Receiving side.

In its response, the Receiving side:
– Returns [ACK] if the transmission is available.
– Returns [NAK] if the transmission is unavailable.
The Sending side must wait 10 seconds before 
re-sending [ENQ].
Sending side Receiving Sending side Receiving

side side
1. [ENQ] 1. [ENQ]
[NAK] 2. [NAK] 2.
3.
10 sec.
…
4. [ENQ]

SUIT Interface
2. When both sides send [ENQ] ([ENQ] clash), the Slave

Computer side has priority over the Host Computer.
– The Slave Computer re-sends [ENQ] 1 second later.
– The Host Computer must wait 20 seconds before re-
sending.
HOST SUIT HOST SUIT

[ENQ] 1. 1. [ENQ]
2. [ENQ] [ENQ] 2.
[ENQ] 3. (1Sec.) Within 20 Sec.

…
3. [ENQ]
3 Note:
LIS should act as slave. A change of these roles has to be
agreed between the deployment staff of Sysmex and LIS.
When SUITplus gets 10 times no answer from host when

doing an "ENQ", SUITplus will close the connection and
establishes a new connection. Be prepared that your driver
accepts this new connection even if the old connection has the
status established at your site.
Keep Alive management:

In order to avoid problems with firewalls when the
communication is idling for 10 minutes SUITplus will send an
"ENQ", wait for your response and close the line by sending an
"EOT".
S: [ENQ]
R: [ACK]
S: [EOT]

SUIT Interface
2.1.2 Forwarding Status
The Sending side transmits a message to the Receiving side.

The following is an example of the text frame structure:
[STX] [F#] [ TEXT ] [ETX] [CHK1] [CHK2] [CR] [LF]
Symbol Code Description

[STX] Indicates the beginning Code to be sent at the beginning of a frame.
of the text Send.
[F#] Frame Number Frame Number is “0” to “7” of ASCII numbers. Its
purpose is to distinguish between sent frame and re-
send frames. This 1-digit number is sent immediately
after STX characters. The Frame Number begins with
“1” when the Forwarding Status starts, and increases
sequentially, every time a new frame is sent and a
positive reply is received.
The Frame Number returns to “0” after “7”, and the
above steps are repeated.
[TEXT] Message Text Employ ASTM E1394-91 Record.
(Refer to explanation of Refer to the "Message Format" in the later section for
ASTM E1238-94) details.
[EXT] Indicates the end of the The code to indicate the end of the final frame.
text Send.
[CHK1] Express with “0” to “F” Add text between [STX] and [ETX] in Binary. Then
[CHK2] characters. take the last 8 bits and express it in Hexadecimal
(2 digits). Then, change the 2-digit number into “0” to
“F” ASCII character format, and save each digit as
CHK1 and CHK2.
[CR] The ASCII Code for Code required before completing an E1394-91 Record
Recovery. (E1381-91 Message) or code that is sent between the
2nd and last within a frame.
[LF] ASCII Code for line LF Code is used for the last character of a frame. LF
changes. cannot be used for Text messages.
2.1.3 End Status

The Sending side sends [EOT] to indicate that all information
has been transmitted to the Receiving side, and turns to the
Idling Status.
Or the Receiving side sends [EOT] when the time out occurs,
and turns to the Idling status. In order for the Sending Side to
start transfer again, turns to the Setting Status.

SUIT Interface
2.1.4 Timeouts
1. In Setting Status, the Sending side sets a 15-second timer

when sending [ENQ]. If there is no response within the 15
seconds, Timeout is applied. The Sending side turns to an
End Status when Timeout occurs.
2. In Forwarding Status, the Sending side sets a 15 seconds

timer after sending the last character of a frame.
If there is no response within the 15 seconds, Timeout is
applied. The Sending side turns to End Status once the
Timeout occurs.
The Receiving side sets the timer for 30 seconds when it
first turns to the Receiving Status or responding to a frame.
If there is no response within 30 seconds, Timeout is
applied. The Receiving side turns to the End Status when
the Timeout occurs.
2.1.5 Restricted message codes
Please find below 10 Transmission Restricted Message

Codes. These (1 type of Format Restriction Code and 4 types
of Instrument Restricted Codes) cannot be used for message
Text.
Restricted Message Codes:
Code Symbol Meaning
SOH (01) Beginning of Header
STX (02) Beginning of Text Sending
ETX (03) End of Text Sending
EOT (04) End of Sending
ENQ (05) Inquiry
ACK (06) Positive Response
DLE (10) Lost Data Link
NAK (15) Negative Response
SYN (16) Simultaneous Signal characters
LF (0A) Change lines
DC1 (11) Instrument Restricted Character 1

SUIT Interface
2.2 Protocol
2.2.1 Orders
SUITplus supports two modes for getting the order by LIS:
1. LIS send the order automatically to Extended IPU when its
registered in LIS
2. LIS send the order to Extended IPU after a query was done
LIS has to support both modes and switching between these
modes has to be possible. This flexibility is needed because
the use of the modes depends on the analyzer the customer
uses and can be changed by modifying the configuration in the
laboratory.
When sending the orders to Extended IPU you can either send
the codes for each parameter to Extended IPU or the codes for
profiles. Refer to chapter Appendix C: Host codes, page 38 to
implement the same codes at your site.
When sending orders for body fluids to Extended IPU it is
mandatory to fill the field collection source (OBR-16,
subfield 2).
Refer to table "Table Codes for Body Fluids" for using the
correct collection source code.
A log file example is currently under construction.
One sample number cannot include orders for different
sections like haematology, coagulation or urine analysis.
Each section needs its own order and its unique sample
number
The logic order of records for sending orders to Extended IPU
is like this. This structure is independent if we operate in query-
mode or download-mode
SUITplus Com. Direction HOST
 ENQ
ACK 
 H: Header Record
ACK 
 P: Patient Record
Repeat
ACK  as many
 C: Patient Comment Record times as
ACK  the No. of
 OBR: Order Record patients
ACK 
 C: Order Comment Record
ACK 
 L: End Mark Record
ACK 
 EOT

SUIT Interface
Details about the records are described at chapter "3 Message

Format".
The logic order of records for doing a query by Extended IPU

to LIS is like this:
ENQ 
 ACK
H: Header Record 
 ACK
Q: Inquiry Record 
 ACK
L: End Mark Record 
 ACK
EOT 

Format".
2.2.2 Results
QC-Results are sent to LIS by using S-Records.Details about

this record are described at chapter "3.8 Scientific Information
Record".

ENQ 
 ACK
 ACK
S: QC Record 
 ACK
 ACK
EOT 
Patient results are sent to LIS by using OBX-Records and C-

Records.

Format".

SUIT Interface
ENQ 
 ACK
 ACK
P: Patient Record 
Repeat as  ACK
many times C: Patient Comment Record 
as the No.
 ACK
of samples
OBR: Order Record 
 ACK
C: Order Comment Record 
 ACK
OBX: Test Result Record 
 ACK
C: Result Comment Record 
 ACK
 ACK
EOT 
3 Note:
The different comment records are set at the following
position:
– the Patient Comment Record in the Patient Free Comment
– Order Comment Record in the Order Free Comment
– Sample Comments, IP Messages (incl. Rule Messages)
and Graphic Data information (File Name) in the Result
Comment Record.
Analyser graphics can be downloaded via shared folder
(optional) Details about this are described at chapter "4.1
Appendix A: Information concerning the graphic-files
management".

Message Format
3 Message Format
3.1 Message and Record

The Record is a type of Text beginning with ASCII (alphabet
code) called Record Descriptor, and ending with [CR]
Record Original Reference

Segment Description
Descriptor Location
Message Header H Section 7 Information Exchange
Management Information
Patient Segment P Section 8 Patient Information
Observation OBR Section 9 Test Order Information
Order Segment
Result Observation OBX Section 10 Test Result Information
Segment
Error Checking E Section 11 Do not use
Segment
Comment Segment C Section 12 Comment Information
Request Results Q Section 13 Order Inquiry
Segment
Message Terminator L Section 14 Message End
Scientific Segment S Section 15 Scientific Information (Used for
QC Data Output)
The Record can be separated into several fields by separators.

The fields are distinguished by their position in the record.
Field lengths are not fixed. The following are types of
separators:
Separator Type Symbol Description

Field | Distinguish between fields within records.
– When there is no contents in a field, send the
separator only.
Repeat ~ Use to distinguish a repeated/multiple same type of
information within a field.
Component ^ Divide a field into several sub-fields.
Sub-component & Defined only in Header. Not used as separator.
Escape \ Defined only in Header. Not used as separator.


Message Format
3.2 Header Record

Header Records include definitions of separators, Version
Information, and the Message Created Date etc.
(Record Format)
H | ^ ~ \ & | | | | | | | | | | | VER | DT<CR>
3 Note:
Mandatory Fields described in Bold Text
Field HOST HOST
Field Field
Field Description Length to from
Code Name
(bytes) SUIT SUIT
H H-1 Segment “H” fixed
1 Y Y
type ID
^~\& H-2 Delimiter Definition of Separators
definition | : Field Separator (7Ch)
^ : Component Separator (5Eh)
~: Repeat Symbol (7Eh) 5 Y Y
\: Escape Symbol (5Ch)
&:Sub-component Separator (26h)
- “\” and “&” Not used.
H-3 Not in use
- - -
H-12
VER H-13 Version Regulated Version Number
“SUITplus1.0” Fixed (ASTM E1238- 20 Y Y
94)
DT H-14 Date and Message Created Date/Time
time of Format:YYYYMMDDHHMM 12 Y Y
message
Mandatory Fields: H-1, H-2, H-13, H-14

Message Format
3.3 Patient Record

Patient Record includes Patient Attribute Information.
(Record Format)
P | SEQ | PID | | APID | NAME | MN | B/D | SEX | | | | | | | | HT | WT
| DIAG | | | | | | ADMS | | | | | | | | DTR <CR>
3 Note:
Field HOST HOST
Field
Field Field Name Description Length to from
Code
(bytes) SUIT SUIT
P P-1 Segment “P” Fixed.
1 Y Y
type ID
SEQ P-2 Trans- Sequence Number. 
mission Sequential from “1” and increase
4 Y Y
sequence by one per patient.
number
PID P-3 Practice Patient ID.
assigned 100 Y Y
patient ID
P-4 Not in use - -
APID P-5 Alter-native Alternative ID. 
100 Y Y
patient ID Use as Public Insurance ID.
NAME P-6 Patient name Patient Name FN^LN
FN : First Name  100 Y Y
LN : Last Name
MN P-7 Mother's Mother’s Maiden Name
Maiden 100 Y Y
name
B/D P-8 Birth Date Date of Birth
8 Y Y
Format: YYYYMMDD
SEX P-9 Patient sex Gender
M: Male,  1 Y Y
F: Female, 
U: Unknown
P-10 Not in use
- - -
P-16
HT P-17 Patient Height:
height cm (w/ decimals)  6 Y Y
or 
feetînch

Message Format
Field HOST HOST

Field
Code
(bytes) SUIT SUIT
WT P-18 Patient Weight:
weight kg (w/ decimals)  6 Y Y
or 
poundôunce
DIAG P-19 Patient's DRG or
diagnoses ICD-9 or
ICD-10 101
Y N
or others 20^80
Code^Name
e.g. D50.0^Bronchitis
P-20 Not in use
- - -
P-24
ADMS P-25 Admission In/Out Patient Differentiation
status 2 Y Y
OP:Out Patient, IP:In Patient
P-26 Not in use
- - -
P-32
DTR P-33 Date/time Data Registration Date
registered (Patient Data/Latest Update Date)  8 Y Y
Format:YYYYMMDD
Mandatory Fields: P-1, P-2

Message Format
3.4 Order Record

(Record Format)
OBR | SEQ | ONO | SNO | TESTID | PRI | RQDT | CLDT | |
CVLM | | ACCD | DGCD | RCINF | RCDT | SRC | DOC |
PHONE | REQ1 | REQ2 | | | DTR | | PSID | | S<CR>
3 Note:
Field HOST HOST
Field
Code
(bytes) SUIT SUIT
OBR OBR-1 Segment type ID “OBR” Fixed. 3 Y Y
SEQ OBR-2 Sequence number Sequence Number
Sequential per OBR record in 4 Y Y
the Patient segment
ONO OBR-3 Requester Sample No. (Barcode No.)*
specimen ID or (HOST side) 100 Y N
accession number
SNO OBR-4 Producer Sample No. (Barcode No.)*
specimen ID or (SUIT side) 100 N Y
accession number
TESTID OBR-5 Observation Test Item
battery ID Code^Name
When ordering multiple orders,
use the Repeat character, “~”, 2000 Y Y
to proceed as below:
Code1^Name1~Code2^Name2
~Code3^Name3 ~ …
PRI OBR-6 Priority Processing Priority Level: 
1 Y Y
S: STAT / Urgent
OBR-7 Requested date- Not in use
- -
time
CLDT OBR-8 Specimen Sample Collection Date/Time 
collection or Format:YYYYMMDDHHMM
12 Y Y
observation date-
time
OBR-9 observation end- Not in use
- -
time
CVLM OBR-10 Collection volume Collection Volume (Urine etc.):
5 Y Y
Unit ml
OBR-11 CollectorID Not in use - -

Message Format
Field HOST HOST

Field
Code
(bytes) SUIT SUIT
ACCD OBR-12 Action code Order Process Code
“L”: register the order and
1 Y N
merge with an existing one.
“C”: Cancel the whole order
OBR-13 Danger code Not in use.
RCINF OBR-14 Relevant clinical Patient Comment, Sample
information Comment
The code for Patient Comment 2000 Y Y
1~2~3~4~5^the code for
Sample Comment1~2
RCDT OBR-15 Date and time of Registration Date/Time 
12 Y Y
specimen receipt Format: YYYYMMDDHHMM
SRC OBR-16 Source of Tube Type Code, Collection
100 Y Y
specimen Source Code
DOC OBR-17 Ordering Doctor Code^Doctor Name 101
Physician Y Y
20^80
PHONE OBR-18 Phone number Order callback phone number
100 Y Y
REQ1 OBR-19 Requestor 1 Clinic Code^Clinic Name 101

Y Y
20^80
REQ2 OBR-20 Requestor 2 Ward Code^Ward Name 101
Y Y
20^80
OBR-21 Not in use
- - -
OBR-22
DTR OBR-23 Date and time Report (Update) Date/Time 
observation Format:YYYYMMDDHHMM
12 N Y
reported 
or status changed
OBR-24 Producer's Not in use
- -
Change
PSID OBR-25 Producer's section
Testing Section ID 20 N Y
ID
OBR-26 Not in use
- - -
OBR-27
QT OBR-28 Quantity- Timing Order Comment Code 6 Y Y
3
Note:
Mandatory Fields: OBR-1, OBR-2, OBR-3, OBR-5, OBR-12,
OBR-15.

Message Format
3 Note:
OBR-16 is mandatory for Bodyfluids
Table Codes for Body fluids
Body Fluid Code

CSF CSF
Ascites ASCITES
Pleural Fluid PLEURAL
CAPD Fluid CAPD
Synovial Fluid SYNOVIA
Example for OBR-16: |^CSF|

Message Format
3.5 Test Result Record

Test Result Record includes information on the received
results.
(Record Format)
OBX | SEQ | VTYPE | OBID | CLA | OBVAL| UNT| REFR |
AFLG | REAG | | ORST | DT | | | PROD | RSPS<CR>
Field HOST HOST

Field
Code
(bytes) SUIT SUIT
OBX OBX-1 Segment type “OBX” Fixed
3 N Y
ID
SEQ OBX-2 Sequence Sequence Number.
number Sequential per OBX Record in 4 N Y
the Order Segment.
VTYPE OBX-3 Value type Test Result Data format
ST:Characters
2 N Y
NM:Numeric Value
CE:Code
OBID OBX-4 Observation Test Item 61
identifier N Y
Code^Name (30^30)
CLA OBX-5 Parameter R = Research
Classification D = Diagnostic 1 N Y
S = Service
OBVA OBX-6 Observation Test Result
L value ^Result Comment
~ Result Comment 1
~Result Comment
~...
^Dilution ratio
E.g these examples are 113

equivalent: (50^20~20 N Y
~20^1)
10^^
10^tel^1
10^^1
10^tel^1
10^&~tel^1
Be prepared for all varieties

Message Format
Field HOST HOST

Field
Code
(bytes) SUIT SUIT
UNT OBX-7 Units Unit (optional) 10 N Y
REFR OBX-8 Reference Reference Ranges
100 - Y
Ranges
AFLG OBX-9 Abnormal flags Abnormal Value Flag:
Upper/Lower Flag
~ Delta Check Flag
L : Low
H : High
5
LL : Panic low N Y
(2~2)
HH : Panic high
> : out if linearity
W : low reliability
A : Abnormal (Except numeric
value data)
REAG OBX-10 Reagent ReagentCode^LotNo^SerialNo
Information When sending multiple reagent
information for one test we use
the repeat character, “~”, to
proceed as below: 200 N Y
ReagentCode^LotNo^SerialNo
~
ReagentCode^LotNo^SerialNo
OBX-11 Not in use - -
ORST OBX-12 Observation Test Result Status
result status ^ Latest Operation
Test Result Status:
P: Preliminary Report
F: Final Result
I: Pending
22
C: Revision Report N Y
(1^20)
Latest Operation:
Edit : input or edit
Validate : manual validate
Count : count at pad menu
Manual Send : send manually
(N/A) : others

Message Format
Field HOST HOST

Field
Code
(bytes) SUIT SUIT
DT OBX-13 Date/Time Sending Date/Time
of last Format:YYYYMMDDHHMM
change in
12 N Y
normal
value or
units
OBX-14 Not in use
- - -
OBX-15
PROD OBX-16 Producers ID AnalyserTypeÎnstrumentID^R 103 N Y
ack^Tube2 25^25^25^
e.g. 25
XN-20Â1000^100125^02
^^^
RSPS OBX-17 Responsible Latest Operator ID
Observer 100 N Y
1. The default result comments are:

“c”: is set when a parameter was re-calculated
“&” is set when WBC, LYMPH# and LYMPH% are compensated by NRBC, when NEUT# and NEUT% are com-
pensated by IG or NRBC or WBC is reported by using WBC-D and PLT is reported by using PLT-O or PLT-F.
2. In case results are produced by the manual differentiation or a result was changed manually by the user -> OBX-
16 is empty
3.6 Comment Record

Comment Record includes the comments for the previous P,
OBR, or OBX Record.
In case of following a P-Record, valid for SUITplus Patient
Free Comments.
In case of following an OBR-Record, valid for SUITplus Order
Free Comments.
In the case of following an OBX Record, valid for Sample Free
Comments, IP Message, Graphic Data Information (File
Name).
(Record Format)
C | SEQ | SOUR | CMT <CR>

Message Format
Field HOST HOST

Field
Code
(bytes) SUIT SUIT
C C-1 Segment type ID “C” Fixed 1 Y Y
Sequence Number.
SEQ C-2 Sequence number 2 Y Y
Sequential per C Record.
Source1^Type2
e.g.  21
SOUR C-3 Comment Source N Y
^ 10^10
^RULE
CMT C-4 Comment text Comment Contents 200 Y Y
1. The
content is empty in case no comment source is defined
2. The
content is empty in case no comment type is defined
To supply the LIMS with the graphical data of the analyzers,

SUITplus is transmitting the filename to host by using a C-
Record.
For more details refer to "4.1 Appendix A"
SUITplus comment Source^Type definition
SOURCE Description
RBC This comment belongs to the red blood cells
WBC This comment belongs to the white blood cells
PLT This comment belongs to the thrombocytes
RET This comment belongs to the reticulocytes
NRBC This comment belongs to the nucleated red blood cells
BF This comment belongs to body fluids
COUNT This comment belongs to the manual differential
HBA This comment belongs to HBA analysis
ESR This comment belongs to ESR analysis
COAGULATION This comment belongs to Coagulation analysis
PATIENT This comment belongs to Patient comment
SAMPLE This comment belongs to Sample comment
INFO This comment belongs to Rule information
URINE This comment belongs to Urine rule
URINALYSIS This comment belongs to UF analysis
HEMATOLOGY This comment belongs to Hematology analysis
DIPSTICK This comment belongs to Dipstick analysis
SP This comment belongs to SP analysis
VALIDATION This comment belongs to validation comment
TYPE Description
IP This is an interpretation flag of the analyser
RULE This is rule created by Sysmex/Customer rules

MORPH This is a morphology comment
GRAPH This is a file name incl. the path
COMMENT This is a general comment type for the source

Message Format
3.7 Order Inquiry Record

In ASTM1238-94, this is used for Previous Order Information
and Result Information Inquiry; however for SUITplus this is
used for the Query (Order Inquiry)
(Record Format)
Q | SEQ | | PROPID | | | DT <CR>
Field HOST HOST

Field
Code
(bytes) SUIT SUIT
Q Q-1 Segment type “Q” Fixed
1 N Y
ID
SEQ Q-2 Sequence Sequence Number: 1 - 9999
number 4 N Y
Q-3 Requestor Not in use

Assigned - -
patient ID
PROPID Q-4 Producer Sample No.~ Sample No.~…..
assigned 200 N Y
patient ID
Q-5 Not in use
- - -
Q-6
DT Q-7 Nature of Registration Date/Time
request Format:YYYYMMDDHHMM 12 N Y
time limits (SUIT sets the Registration Date)

Message Format
3.8 Scientific Information Record

(Record Format)
S | SEQ | METH | INST | | | QC | | | | SID | ANA | RESULT
| | | DT<CR>
Field HOST HOST

Field
Code
(bytes) SUIT SUIT
Segment
S S-1 “S” Fixed 1 N Y
type ID
Sequence
SEQ S-2 Sequence Number: 1 – 9999 4 N Y
number
Analytical Mode:
METH S-3 20 N Y
Method “Manual” or “Closed”
Instrumentati Analyzer Name or Instrument

INST S-4 20 N Y
on ID
S-5
- Not in use - -
S-6
Quality
QC S-7 “QC” Fixed 2 N Y
Control
S-8
- Not in use - -
S-10
SID S-11 Specimen ID Lot Number of Control Reagent 100 N Y
ANA S-12 Analytic Analysis Item Name 20 N Y
RESULT S-13 Result QC Data 8 N Y
S-14
- Not in use - -
S-15
Analysis
Measurement Date/Time
DT S-16 Date and 12 N Y
YYYYMMDDHHMM
time

Message Format
3.9 End Mark Record

(Record Format)
L | SEQ | | PCNT | LCNT <CR>
3 Note:
Field HOST HOST

Field
Code
(bytes) SUIT SUIT
Segment
L L-1 “L” Fixed 1 Y Y
type ID
Sequence
SEQ L-2 Sequence Number: 1 1 Y Y
number
L-3 Not in use - -
Total number of P Records in

PCNT L-4 Patient count 4 Y Y
message.
Total number of records, (end

LCNT L-5 Line count 10 Y Y
with <CR>), in message.
Mandatory Fields: L-1, L-2, L-4, L-5.

Appendixes
Appendixes
4 Appendixes
4.1 Appendix A: Information concerning the graphic-files management

SUITplus is sending the graphics including the subfolders as
png. The character string “&r&” in the name is representing a
“\ ”.
Cut out these files from the specified location.
Example:
S:STX]6C|6||PNG&R&20110808&R&2011_08_08_11_02_2a
361165-10b7-496a-b4ce-
dc8a373b6f89_PLT.PNG[0Dh][ETX]55[0Dh][0Ah]
Refer log file example at chapter "4.2.4 Result from Extended
IPU to LIS with graph info".
The following graphics are available:

Graphic Name Section Type
WBC_BASO HAEMATOLOGY PNG
RBC HAEMATOLOGY PNG
PLT HAEMATOLOGY PNG
PLT_O HAEMATOLOGY PNG
DIFF HAEMATOLOGY PNG
IMI HAEMATOLOGY PNG
NRBC HAEMATOLOGY PNG
RET HAEMATOLOGY PNG
RET_EXT HAEMATOLOGY PNG
RBC-Y HAEMATOLOGY PNG
WDF HAEMATOLOGY PNG
WNR HAEMATOLOGY PNG
WPC HAEMATOLOGY PNG
PLT_F HAEMATOLOGY PNG
WDF_FSC HAEMATOLOGY PNG
RBC_FSC HAEMATOLOGY PNG
WDF_EXT_BF HAEMATOLOGY PNG

Appendixes
4.2 Appendix B: Examples of Logfiles

The log files below are examples and could slightly differ
depending on customer specific configuration.
4.2.1 Query from Extended IPU to LIS:
12-05-2012 10:02:36 530 : R: [ENQ]

12-05-2012 10:02:36 530 : S: [ACK]
12-05-2012 10:02:36 560 : R: [STX]1H|^~\&|||||||||||SUITplus1.0|201205121002[0Dh][ETX]1B[0Dh][0Ah]
12-05-2012 10:02:36 570 : S: [ACK]
12-05-2012 10:02:36 590 : R: [STX]2Q|1||SAMPLE ID|||[0Dh][ETX]1B[0Dh][0Ah]
12-05-2012 10:02:36 600 : S: [ACK]
12-05-2012 10:02:36 620 : R: [STX]3L|1||0|3[0Dh][ETX]13[0Dh][0Ah]
12-05-2012 10:02:36 630 : S: [ACK]
12-05-2012 10:02:36 650 : R: [EOT]
4.2.2 Order from LIS to Extended IPU when order exists:
12-05-2012 10:11:04 418 : S: [ENQ]

12-05-2012 10:11:04 448 : R: [ACK]
12-05-2012 10:11:04 468 : S: [STX]1H|^~\&|||||||||||SUITplus1.0|201205121011[0Dh][ETX]1B[0Dh][0Ah]
12-05-2012 10:11:04 518 : R: [ACK]
12-05-2012 10:11:04 538 : S:
[STX]2P|1|PATIENTID|||FIRSTNAME^LASTNAME||19770512|F||||||||175|70|DIAGNOSIS||||||OP||||||||201205
12[0Dh][ETX]F8[0Dh][0Ah]
12-05-2012 10:11:04 568 : R: [ACK]
12-05-2012 10:11:04 588 : S: [STX]3C|1||FREE PATIENT COMMENT[0Dh][ETX]B5[0Dh][0Ah]
12-05-2012 10:11:04 618 : R: [ACK]
12-05-2012 10:11:04 638 : S: [STX]4OBR|1|SAMPLE
ID||wbc~plt~rbc~hgb~neut#~neut%~lymph#~lymph%~mono#~mono%~eo#~eo%~baso#~baso%~ig#~ig%||
|201205121011||5||L||PATIENT COMMENTS^SAMPLE
COMMENTS|201205121011|TUBE^COLL|DOCTOR^DOCTOR
NAME|PHONE|CLINIC|WARD|||201205121011|||||[0Dh][ETX]AA[0Dh][0Ah]
12-05-2012 10:11:04 668 : R: [ACK]
12-05-2012 10:11:04 688 : S: [STX]5C|1||FREE ORDER COMMENT[0Dh][ETX]1E[0Dh][0Ah]
12-05-2012 10:11:04 718 : R: [ACK]
12-05-2012 10:11:04 738 : S: [STX]6L|1||1|4[0Dh][ETX]18[0Dh][0Ah]
12-05-2012 10:11:04 768 : R: [ACK]
12-05-2012 10:11:04 788 : S: [EOT]
4.2.3 Reply from LIS to Extended IPU when no order exists:
12-05-2012 10:07:33 780 : S: [ENQ]

12-05-2012 10:07:33 810 : R: [ACK]
12-05-2012 10:07:33 830 : S: [STX]1H|^~\&|||||||||||SUITplus1.0|201205121007[0Dh][ETX]20[0Dh][0Ah]
12-05-2012 10:07:33 860 : R: [ACK]
12-05-2012 10:07:33 880 : S: [STX]2P|1||||^|||U||||||||||||||||OP||||||||20120512[0Dh][ETX]AF[0Dh][0Ah]
12-05-2012 10:07:33 910 : R: [ACK]
12-05-2012 10:07:33 930 : S: [STX]3OBR|1|SAMPLE
ID|||||201205121007||||L|||201205121007|^|^||||||201205121007|||||[0Dh][ETX]E1[0Dh][0Ah]
12-05-2012 10:07:33 960 : R: [ACK]
12-05-2012 10:07:33 980 : S: [STX]4L|1||1|4[0Dh][ETX]16[0Dh][0Ah]
12-05-2012 10:07:34 10 : R: [ACK]

12-05-2012 10:07:34 30 : S: [EOT]

Appendixes
4.2.4 Result from Extended IPU to LIS with graph info
Results from Extended IPU to LIS with image path, calculated

results (MCH, MCHC) and changed results (HGB) with no
analyzer info:
01-10-2012 10:14:09 117 : R: [ENQ]

01-10-2012 10:14:09 117 : S: [ACK]
01-10-2012 10:14:09 147 : R: [STX]1H|^~\&|||||||||||SUITplus1.0|201210011014[0Dh][ETX]18[0Dh][0Ah]
01-10-2012 10:14:09 157 : S: [ACK]
01-10-2012 10:14:09 177 : R: [STX]2P|1|Patient ID|||First Name^Last
Name||19821001|M||||||||178.0|85.0|||||||OP||||||||20121001[0Dh][ETX]D3[0Dh][0Ah]
01-10-2012 10:14:09 187 : S: [ACK]
01-10-2012 10:14:09 207 : R: [STX]3C|1|PATIENT^COMMENT|Free Patient Comment[0Dh][ETX]1B[0Dh][0Ah]
01-10-2012 10:14:09 217 : S: [ACK]
01-10-2012 10:14:09 237 : R: [STX]4C|2|PATIENT^COMMENT|PCOM[0Dh][ETX]E2[0Dh][0Ah]
01-10-2012 10:14:09 247 : S: [ACK]
01-10-2012 10:14:09 266 : R: [STX]5OBR|1||Sample
ID|WBC^WBC~HCT^HCT~HGB^HGB~MCH^MCH~MCHC^MCHC~MCV^MCV~RDW-CV^RDW-CV~RDW-
SD^RDW-SD~RBC^RBC~MPV^MPV~P-LCR^P-
LCR~PCT^PCT~PDW^PDW~PLT^PLT~BASO#^BASO#~BASO%^BASO%~EO#ÊO#~EO%ÊO%~IG#Î
G#~IG%ÎG%~LYMPH#^LYMPH#~LYMPH%^LYMPH%~MONO#^MONO#~MONO%^MONO%~NEUT#^N
EUT#~NEUT%^NEUT%~NRBC%^NRBC%~NRBC#^NRBC#|S||201210011006||||||||^Collection
Source|Doctor^Doctor Name|Phone|Clinic^|Ward^|||201210011014||001|||[0Dh][ETX]FD[0Dh][0Ah]
01-10-2012 10:14:09 276 : S: [ACK]
01-10-2012 10:14:09 296 : R: [STX]6C|1|SAMPLE^COMMENT|SCOM[0Dh][ETX]93[0Dh][0Ah]
01-10-2012 10:14:09 306 : S: [ACK]
01-10-2012 10:14:09 326 : R: [STX]7C|2|SAMPLE^COMMENT|Free Sample Comment[0Dh][ETX]5A[0Dh][0Ah]
01-10-2012 10:14:09 336 : S: [ACK]
01-10-2012 10:14:09 356 : R: [STX]0C|3|SAMPLE^COMMENT|Free Sample COmment[0Dh][ETX]34[0Dh][0Ah]
01-10-2012 10:14:09 366 : S: [ACK]
01-10-2012 10:14:09 386 : R: [STX]1C|4|INFO^RULE|Analyser error -> Please check
IPU[0Dh][ETX]A8[0Dh][0Ah]
01-10-2012 10:14:09 396 : S: [ACK]
01-10-2012 10:14:09 416 : R: [STX]2C|5|INFO^RULE|Capillary sample -> Check scattergrams and
histograms[0Dh][ETX]A0[0Dh][0Ah]
01-10-2012 10:14:09 426 : S: [ACK]
01-10-2012 10:14:09 446 : R: [STX]3C|6|RBC^RULE|Lipaemia / haemolysis / agglutinins? -> Check
sample[0Dh][ETX]EA[0Dh][0Ah]
01-10-2012 10:14:09 456 : S: [ACK]
01-10-2012 10:14:09 476 : R: [STX]4C|7|RBC^RULE|HGB > Linearity limit -> Dilute
sample![0Dh][ETX]B3[0Dh][0Ah]
01-10-2012 10:14:09 486 : S: [ACK]
01-10-2012 10:14:09 506 : R: [STX]5C|8|VALIDATION^COMMENT|Validation
Comment[0Dh][ETX]8E[0Dh][0Ah]
01-10-2012 10:14:09 516 : S: [ACK]
01-10-2012 10:14:09 536 : R: [STX]6OBX|1|NM|WBC^WBC|D|6.10^|10*3/µL|3.90-10.20||NR^Z1234^Serial
Number~CL^Z1234^Serial Number~WN^Z1234^Serial Number~ST^Z1234^Serial
Number||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]02[0Dh][0Ah]
01-10-2012 10:14:09 546 : S: [ACK]
01-10-2012 10:14:09 566 : R: [STX]7OBX|2|NM|HCT^HCT|D|46.0^|%|39.5-50.5|A|CL^Z1234^Serial
Number~ST^Z1234^Serial Number||F^Validate|201210011014|||XN-20^Serial
Number^100125^02|Support[0Dh][ETX]8E[0Dh][0Ah]
01-10-2012 10:14:09 576 : S: [ACK]
01-10-2012 10:14:09 596 : R: [STX]0OBX|3|NM|HGB^HGB|D|15.1^|g/dL|13.5-17.2|>|CL^Z1234^Serial
Number~SL^Z1234^Serial Number~ST^Z1234^Serial Number||F^Validate|201210011014|||XN-20^Serial
Number^100125^02|Support[0Dh][ETX]65[0Dh][0Ah]
01-10-2012 10:14:09 606 : S: [ACK]
01-10-2012 10:14:09 626 : R: [STX]1OBX|4|NM|MCH^MCH|D|30.0^|pg|27.0-
33.5||||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]99[0Dh][0Ah]

Appendixes
01-10-2012 10:14:09 636 : S: [ACK]

01-10-2012 10:14:09 656 : R: [STX]2OBX|5|NM|MCHC^MCHC|D|40.8^|g/dL|31.5-
36.0||||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]97[0Dh][0Ah]
01-10-2012 10:14:09 666 : S: [ACK]
01-10-2012 10:14:09 686 : R: [STX]3OBX|6|NM|MCV^MCV|D|98.1^|fL|80.0-
99.0||||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]A9[0Dh][0Ah]
01-10-2012 10:14:09 696 : S: [ACK]
01-10-2012 10:14:09 716 : R: [STX]4OBX|7|NM|RDW-CV^RDW-
CV|D|17.0^|%|||||F^Validate|201210011014|||XN-20^Serial
Number^100125^02|Support[0Dh][ETX]EB[0Dh][0Ah]
01-10-2012 10:14:09 726 : S: [ACK]
01-10-2012 10:14:09 746 : R: [STX]5OBX|8|NM|RDW-SD^RDW-
SD|D|57.0^|fL|||||F^Validate|201210011014|||XN-20^Serial
Number^100125^02|Support[0Dh][ETX]7A[0Dh][0Ah]
01-10-2012 10:14:09 756 : S: [ACK]
01-10-2012 10:14:09 776 : R: [STX]6OBX|9|NM|RBC^RBC|D|6.32^@|10*6/µL|4.30-5.75||CL^Z1234^Serial
Number^100125^02|Support[0Dh][ETX]4D[0Dh][0Ah]
01-10-2012 10:14:09 786 : S: [ACK]
01-10-2012 10:14:09 806 : R: [STX]7OBX|10|NM|MPV^MPV|D|11.4^|fL|||||F^Validate|201210011014|||XN-
20^Serial Number^100125^02|Support[0Dh][ETX]23[0Dh][0Ah]
01-10-2012 10:14:09 816 : S: [ACK]
01-10-2012 10:14:09 836 : R: [STX]0OBX|11|NM|P-LCR^P-LCR|D|39.9^|%|||||F^Validate|201210011014|||XN-
01-10-2012 10:14:09 846 : S: [ACK]
01-10-2012 10:14:09 866 : R: [STX]1OBX|12|NM|PCT^PCT|D|0.2^|%|||CL^Z1234^Serial
Number^100125^02|Support[0Dh][ETX]8C[0Dh][0Ah]
01-10-2012 10:14:09 876 : S: [ACK]
01-10-2012 10:14:09 896 : R: [STX]2OBX|13|NM|PDW^PDW|D|16.0^|fL|||||F^Validate|201210011014|||XN-
01-10-2012 10:14:09 906 : S: [ACK]
01-10-2012 10:14:09 926 : R: [STX]3OBX|14|CE|PLT^PLT|D|ERROR^|10*3/µL|150-400||CL^Z1234^Serial
Number^100125^02|Support[0Dh][ETX]A9[0Dh][0Ah]
01-10-2012 10:14:09 936 : S: [ACK]
01-10-2012 10:14:09 956 : R: [STX]4C|1|^|Manual Result Comment[0Dh][ETX]7A[0Dh][0Ah]
01-10-2012 10:14:09 966 : S: [ACK]
01-10-2012 10:14:09 986 : R: [STX]5OBX|15|NM|BASO#^BASO#|D|0.08^|10*3/µL|0.00-0.20||NR^Z1234^Serial
Number||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]D2[0Dh][0Ah]
01-10-2012 10:14:09 996 : S: [ACK]
01-10-2012 10:14:10 16 : R: [STX]6OBX|16|NM|BASO%^BASO%|D|0.4^|%|0.0-1.8||NR^Z1234^Serial
01-10-2012 10:14:10 26 : S: [ACK]
01-10-2012 10:14:10 46 : R: [STX]7OBX|17|NM|EO#ÊO#|D|0.12^|10*3/µL|0.02-0.50||DF^Z1234^Serial
Number~CL^Z1234^Serial Number~WD^Z1234^Serial Number~ST^Z1234^Serial
01-10-2012 10:14:10 56 : S: [ACK]
01-10-2012 10:14:10 76 : R: [STX]0OBX|18|NM|EO%ÊO%|D|0.9^|%|0.5-5.5||DF^Z1234^Serial
01-10-2012 10:14:10 86 : S: [ACK]
01-10-2012 10:14:10 106 : R: [STX]1OBX|19|NM|IG#ÎG#|D|0.01^|10*3/µL|||DF^Z1234^Serial
Number||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]D6[0Dh][0Ah]
01-10-2012 10:14:10 116 : S: [ACK]

01-10-2012 10:14:10 136 : R: [STX]2OBX|20|NM|IG%ÎG%|D|0.1^|%|||DF^Z1234^Serial
Number||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]DA[0Dh][0Ah]

Appendixes
01-10-2012 10:14:10 146 : S: [ACK]

01-10-2012 10:14:10 166 : R: [STX]3OBX|21|NM|LYMPH#^LYMPH#|D|3.79^|10*3/µL|1.10-
4.50||DF^Z1234^Serial Number~CL^Z1234^Serial Number~WD^Z1234^Serial Number~ST^Z1234^Serial
Number||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]8B[0Dh][0Ah]
01-10-2012 10:14:10 176 : S: [ACK]
01-10-2012 10:14:10 196 : R: [STX]4OBX|22|NM|LYMPH%^LYMPH%|D|29.1^|%|20.0-40.0||DF^Z1234^Serial
Number||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]BC[0Dh][0Ah]
01-10-2012 10:14:10 206 : S: [ACK]
01-10-2012 10:14:10 226 : R: [STX]5OBX|23|NM|MONO#^MONO#|D|0.50^|10*3/µL|0.10-
0.90||DF^Z1234^Serial Number~CL^Z1234^Serial Number~WD^Z1234^Serial Number~ST^Z1234^Serial
Number||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]DE[0Dh][0Ah]
01-10-2012 10:14:10 236 : S: [ACK]
01-10-2012 10:14:10 256 : R: [STX]6OBX|24|NM|MONO%^MONO%|D|8.4^|%|2.0-9.5||DF^Z1234^Serial
01-10-2012 10:14:10 266 : S: [ACK]
01-10-2012 10:14:10 286 : R: [STX]7OBX|25|NM|NEUT#^NEUT#|D|7.28^|10*3/µL|1.50-7.70||DF^Z1234^Serial
Number||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]FE[0Dh][0Ah]
01-10-2012 10:14:10 296 : S: [ACK]
01-10-2012 10:14:10 316 : R: [STX]0OBX|26|NM|NEUT%^NEUT%|D|55.4^|%|42.0-77.0||DF^Z1234^Serial
01-10-2012 10:14:10 326 : S: [ACK]
01-10-2012 10:14:10 346 : R: [STX]1OBX|27|NM|NRBC%^NRBC%|D|4.0^|/100WBC|||NR^Z1234^Serial
Number||F^Validate|201210011014|||XN-20^Serial Number^100125^02|Support[0Dh][ETX]A4[0Dh][0Ah]
01-10-2012 10:14:10 356 : S: [ACK]
01-10-2012 10:14:10 376 : R: [STX]2OBX|28|NM|NRBC#^NRBC#|D|5.00^|10*3/µL|||NR^Z1234^Serial
01-10-2012 10:14:10 386 : S: [ACK]
01-10-2012 10:14:10 406 : R: [STX]3C|1|HEMATOLOGY^COMMENT|Error_Func[0Dh][ETX]8A[0Dh][0Ah]
01-10-2012 10:14:10 416 : S: [ACK]
01-10-2012 10:14:10 436 : R: [STX]4C|2|RBCÎP|Turbidity/HGB_Interference?[0Dh][ETX]33[0Dh][0Ah]
01-10-2012 10:14:10 446 : S: [ACK]
01-10-2012 10:14:10 466 : R:
[STX]5C|3|WBC^GRAPH|PNG&R&20121001&R&2012_10_01_10_14_7c9289b9-b9ec-4ce9-8f97-
666472897e20_WPC.PNG[0Dh][ETX]20[0Dh][0Ah]
01-10-2012 10:14:10 476 : S: [ACK]
01-10-2012 10:14:10 496 : R:
[STX]6C|4|WBC^GRAPH|PNG&R&20121001&R&2012_10_01_10_14_96b165a0-c5c8-4ab0-967c-
5aa21abb8b5a_WDF.PNG[0Dh][ETX]C4[0Dh][0Ah]
01-10-2012 10:14:10 506 : S: [ACK]
01-10-2012 10:14:10 526 : R:
[STX]7C|5|NRBC^GRAPH|PNG&R&20121001&R&2012_10_01_10_14_4459b6e7-8296-461e-8665-
4e2f56829919_WNR.PNG[0Dh][ETX]B3[0Dh][0Ah]
01-10-2012 10:14:10 536 : S: [ACK]
01-10-2012 10:14:10 556 : R: [STX]0C|6|RBC^GRAPH|PNG&R&20121001&R&2012_10_01_10_14_3f10596d-
7ada-4ca8-be28-e551a78ba3ea_RBC.PNG[0Dh][ETX]ED[0Dh][0Ah]
01-10-2012 10:14:10 566 : S: [ACK]
01-10-2012 10:14:10 586 : R: [STX]1C|7|PLT^GRAPH|PNG&R&20121001&R&2012_10_01_10_14_3c66b2f6-
9b02-4256-a298-95a00c818e74_PLT.PNG[0Dh][ETX]DC[0Dh][0Ah]
01-10-2012 10:14:10 596 : S: [ACK]
01-10-2012 10:14:10 616 : R: [STX]2L|1||1|50[0Dh][ETX]45[0Dh][0Ah]
01-10-2012 10:14:10 626 : S: [ACK]
01-10-2012 10:14:10 746 : R: [EOT]

Appendixes
4.2.5 Quality Control log files
There are two methods to send a quality control results from

the analyzer to the host.
Method 1:
One method is that the user is sending the quality control out
of the IPU’s sample explorer. In this case the sample will get
the lot number of the actual QC as sample number.
E.g.: QC-51470801
For each parameter the analyzer-id and the measurement-
mode is transmitted, too.
S: [ENQ]
R: [ACK]
S: [STX]1H|^~\&| | | | | | | | | | |A.2|200506271532[CR][ETX]35[CR][LF]
R: [ACK]
S: [STX]2S|1|Manual|A2424| | | QC| | | | QC-51470801|WBC|2.27| | | 20050627153202|[CR][ETX]C8[CR][LF]
R: [ACK]
S: [STX]3S|2|Manual|A2424| | | QC| | | | QC-51470801|RBC|2.30| | | 20050627153202|[CR][ETX]BF[CR][LF]
R: [ACK]
S: [STX]4S|3|Manual|A2424| | | QC| | | | QC-51470801|HGB|6.0| | | 20050627153202|[CR][ETX]8C[CR][LF]
R: [ACK]
S: [STX]5S|4|Manual|A2424| | | QC| | | | QC-51470801|HCT|17.6| | | 20050627153202|[CR][ETX]D4[CR][LF]
R: [ACK]
S: [STX]6S|5|Manual|A2424| | | QC| | | | QC-51470801|MCV|76.5| | | 20050627153202|[CR][ETX]E1[CR][LF] | | |
| R: [ACK]
S: [STX]1S|16|Manual|A2424| | | QC| | | | QC-51470801|MONO#|0.24| | |
20050627153202|[CR][ETX]78[CR][LF]
R: [ACK]
S: [STX]2S|17|Manual|A2424| | | QC| | | | QC-51470801|EO#|0.17| | | 20050627153202|[CR][ETX]D7[CR][LF]
R: [ACK]
S: [STX]3S|18|Manual|A2424| | | QC| | | | QC-51470801|BASO#|1.38| | |
20050627153202|[CR][ETX]6E[CR][LF]
R: [ACK]
S: [STX]4S|19|Manual|A2424| | | QC| | | | QC-51470801|IG%|10.1| | | 20050627153202|[CR][ETX]D3[CR][LF]
R: [ACK]
S: [STX]5S|20|Manual|A2424| | | QC| | | | QC-51470801|IG#|0.23| | | 20050627153202|[CR][ETX]CD[CR][LF]
R: [ACK]
S: [STX]6S|21|Manual|A2424| | | QC| | | | QC-51470801|NRBC%|100.0| | | 20050627153202 |[CR][ETX]92
[CR][LF]
R: [ACK]
S: [STX]7S|22|Manual|A2424| | | QC| | | | QC-51470801|NRBC#|2.38| | | 20050627153202 |[CR][ETX]6E
[CR][LF]
R: [ACK]
S: [STX]0S|23|Manual|A2424| | | QC| | | | QC-51470801|RDW-SD|42.7| | | 20050627153202 |[CR][ETX]D1[CR]
[LF]
R: [ACK]
S: [STX]1S|24|Manual|A2424| | | QC| | | | QC-51470801|RDW-CV|15.3| | | 20050627153202 |[CR][ETX]D1
[CR][LF]
R: [ACK]
S: [STX]2S|25|Manual|A2424| | | QC| | | | QC-51470801|PDW|9.1| | | 20050627153202|[CR][ETX]DC[CR][LF]
R: [ACK]
S: [STX]3S|26|Manual|A2424| | | QC| | | | QC-51470801|MPV|9.8| | | 20050627153202|[CR][ETX]ED[CR][LF]
S: [STX]4S|27|Manual|A2424| | | QC| | | | QC-51470801|P-LCR|19.6| | | 20050627153202|[CR][ETX]89[CR][LF]
R: [ACK]
R: [ACK]

Appendixes
S: [STX]5S|28|Manual|A2424| | | QC| | | | QC-51470801|PCT|0.05| | | 20050627153202|[CR][ETX]09[CR][LF]

R: [ACK]
S: [STX]6S|29|Manual|A2424| | | QC| | | | QC-51470801|RET%|6.92| | | 20050627153202|[CR][ETX]40[CR][LF]
R: [ACK]
S: [STX]7S|30|Manual|A2424| | | QC| | | | QC-51470801|RET#|0.1592| | | 20050627153202|[CR][ETX]97[CR][LF]
R: [ACK]
S: [STX]0S|31|Manual|A2424| | | QC| | | | QC-51470801|IRF|36.6| | | 20050627153202|[CR][ETX]02[CR][LF]
R: [ACK]
S: [STX]1S|32|Manual|A2424| | | QC| | | | QC-51470801|LFR|63.4| | | 20050627153202|[CR][ETX]05[CR][LF]
R: [ACK]
S: [STX]2S|33|Manual|A2424| | | QC| | | | QC-51470801|MFR|29.7| | | 20050627153202|[CR][ETX]0D[CR][LF]
R: [ACK]
S: [STX]3S|34|Manual|A2424| | | QC| | | | QC-51470801|HFR|6.9| | | 20050627153202|[CR][ETX]D7[CR][LF]
R: [ACK]
S: [STX]4S|35|Manual|A2424| | | QC| | | | QC-51470801|RET-HE|20.7| | |
20050627153202|[CR][ETX]C8[CR][LF]
R: [ACK]
S: [STX]5S|36|Manual|A2424| | | QC| | | | QC-51470801|IPF|22.2| | | 20050627153202|[CR][ETX]01[CR][LF]
...

Appendixes
Method 2:
Another method consists that the user will send the quality by
using the QC-Charts of the analyzer. In this case the file
number of the charts will be used as sample number.
E.g.: 11 for the file no. 11
S: [ENQ]
R: [ACK]
S: [STX]1H|^~\&| | | | | | | | | | |A.2|200506271532[CR][ETX]35[CR][LF]
R: [ACK]
S: [STX]2S|1|Manual|A2424| | | QC| | | | 11|WBC|2.27| | | 20050627153207|[CR][ETX]54[CR][LF]
R: [ACK]
S: [STX]3S|2|Manual|A2424| | | QC| | | | 11|RBC|2.30| | | 20050627153207|[CR][ETX]4B[CR][LF]
R: [ACK]
S: [STX]4S|3|Manual|A2424| | | QC| | | | 11|HGB|6.0| | | 20050627153207|[CR][ETX]18[CR][LF]
R: [ACK]
S: [STX]5S|4|Manual|A2424| | | QC| | | | 11|HCT|17.6| | | 20050627153207|[CR][ETX]60[CR][LF]
R: [ACK]
S: [STX]6S|5|Manual|A2424| | | QC| | | | 11|MCV|76.5| | | 20050627153207|[CR][ETX]6D[CR][LF]
R: [ACK]
S: [STX]7S|6|Manual|A2424| | | QC| | | | 11|MCH|26.1| | | 20050627153207|[CR][ETX]58[CR][LF]
R: [ACK]
S: [STX]0S|7|Manual|A2424| | | QC| | | | 11|MCHC|34.1| | | 20050627153207|[CR][ETX]94[CR][LF]
R: [ACK]
S: [STX]1S|8|Manual|A2424| | | QC| | | | 11|PLT|54| | | 20050627153207|[CR][ETX]0E[CR][LF]
R: [ACK]
S: [STX]2S|9|Manual|A2424| | | QC| | | | 11|NEUT%|44.9| | | 20050627153207|[CR][ETX]E7[CR][LF]
R: [ACK]
S: [STX]3S|10|Manual|A2424| | | QC| | | | 11|LYMPH%|37.0| | | 20050627153207|[CR][ETX]57[CR][LF]
R: [ACK]
S: [STX]4S|11|Manual|A2424| | | QC| | | | 11|MONO%|10.6| | | 20050627153207|[CR][ETX]05[CR][LF]
R: [ACK]
S: [STX]5S|12|Manual|A2424| | | QC| | | | 11|EO%|7.5| | | 20050627153207|[CR][ETX]37[CR][LF]
R: [ACK]
S: [STX]6S|13|Manual|A2424| | | QC| | | | 11|BASO%|60.8| | | 20050627153207|[CR][ETX]FC[CR][LF]
R: [ACK]
S: [STX]7S|14|Manual|A2424| | | QC| | | | 11|NEUT#|1.02| | | 20050627153207|[CR][ETX]08[CR][LF]
R: [ACK]
S: [STX]0S|15|Manual|A2424| | | QC| | | | 11|LYMPH#|0.84| | | 20050627153207|[CR][ETX]59[CR][LF]
R: [ACK]
S: [STX]1S|16|Manual|A2424| | | QC| | | | 11|MONO#|0.24| | | 20050627153207|[CR][ETX]04[CR][LF]
R: [ACK]
S: [STX]2S|17|Manual|A2424| | | QC| | | | 11|EO#|0.17| | | 20050627153207|[CR][ETX]63[CR][LF]
R: [ACK]
S: [STX]3S|18|Manual|A2424| | | QC| | | | 11|BASO#|1.38| | | 20050627153207|[CR][ETX]FA[CR][LF]
R: [ACK]
S: [STX]4S|19|Manual|A2424| | | QC| | | | 11|IG%|10.1| | | 20050627153207|[CR][ETX]5F[CR][LF]
R: [ACK]
S: [STX]5S|20|Manual|A2424| | | QC| | | | 11|IG#|0.23| | | 20050627153207|[CR][ETX]59[CR][LF]
R: [ACK]
S: [STX]6S|21|Manual|A2424| | | QC| | | | 11|NRBC%|100.0| | | 20050627153207|[CR][ETX]1E[CR][LF]
R: [ACK]
S: [STX]7S|22|Manual|A2424| | | QC| | | | 11|NRBC#|2.38| | | 20050627153207|[CR][ETX]FA[CR][LF]
R: [ACK]
S: [STX]0S|23|Manual|A2424| | | QC| | | | 11|RDW-SD|42.7| | | 20050627153207|[CR][ETX]5D[CR][LF]
R: [ACK]
S: [STX]1S|24|Manual|A2424| | | QC| | | | 11|RDW-CV|15.3| | | 20050627153207|[CR][ETX]5D[CR][LF]

Appendixes
R: [ACK]
S: [STX]2S|25|Manual|A2424| | | QC| | | | 11|PDW|9.1| | | 20050627153207|[CR][ETX]68[CR][LF]
R: [ACK]
S: [STX]3S|26|Manual|A2424| | | QC| | | | 11|MPV|9.8| | | 20050627153207|[CR][ETX]79[CR][LF]
R: [ACK]
S: [STX]4S|27|Manual|A2424| | | QC| | | | 11|P-LCR|19.6| | | 20050627153207|[CR][ETX]15[CR][LF]
R: [ACK]
S: [STX]5S|28|Manual|A2424| | | QC| | | | 11|PCT|0.05| | | 20050627153207|[CR][ETX]95[CR][LF]
R: [ACK]
S: [STX]6S|29|Manual|A2424| | | QC| | | | 11|RET%|6.92| | | 20050627153207|[CR][ETX]CC[CR][LF]
R: [ACK]
RS: [STX]7S|30|Manual|A2424| | | QC| | | | 11|RET#|0.1592| | | 20050627153207|[CR][ETX]23[CR][LF]
R: [ACK]
S: [STX]0S|31|Manual|A2424| | | QC| | | | 11|IRF|36.6| | | 20050627153207|[CR][ETX]8E[CR][LF]
R: [ACK]
S: [STX]1S|32|Manual|A2424| | | QC| | | | 11|LFR|63.4| | | 20050627153207|[CR][ETX]91[CR][LF]
R: [ACK]
S: [STX]2S|33|Manual|A2424| | | QC| | | | 11|MFR|29.7| | | 20050627153207|[CR][ETX]99[CR][LF]
R: [ACK]
S: [STX]3S|34|Manual|A2424| | | QC| | | | 11|HFR|6.9| | | 20050627153207|[CR][ETX]63[CR][LF]
R: [ACK]
S: [STX]4S|35|Manual|A2424| | | QC| | | | 11|RET-HE|20.7| | | 20050627153207|[CR][ETX]54[CR][LF]
R: [ACK]
S: [STX]5S|36|Manual|A2424| | | QC| | | | 11|IPF|22.2| | | 20050627153207|[CR][ETX]8D[CR][LF]
R: [ACK]
S: [STX]6S|37|Manual|A2424| | | QC| | | | 11|BASO-X|112.4| | | 20050627153207|[CR][ETX]8C[CR][LF]
R: [ACK]
S: [STX]7S|38|Manual|A2424| | | QC| | | | 11|BASO-Y|123.6| | | 20050627153207|[CR][ETX]93[CR][LF]
R: [ACK]
S: [STX]0S|39|Manual|A2424| | | QC| | | | 11|DIFF-X|152.8| | | 20050627153207|[CR][ETX]84[CR][LF]
R: [ACK]
S: [STX]1S|40|Manual|A2424| | | QC| | | | 11|DIFF-Y|62.5| | | 20050627153207|[CR][ETX]4B[CR][LF]
R: [ACK]
S: [STX]2S|41|Manual|A2424| | | QC| | | | 11|NRBC-X|197.5| | | 20050627153207|[CR][ETX]91[CR][LF]
R: [ACK]
S: [STX]3S|42|Manual|A2424| | | QC| | | | 11|NRBC-Y|131.7| | | 20050627153207|[CR][ETX]8A[CR][LF]
R: [ACK]
S: [STX]4S|43|Manual|A2424| | | QC| | | | 11|IMI#|1182| | | 20050627153207|[CR][ETX]B5[CR][LF]
R: [ACK]
S: [STX]5S|44|Manual|A2424| | | QC| | | | 11|IMI-DC|503.9| | | 20050627153207|[CR][ETX]7B[CR][LF]
R: [ACK]
S: [STX]6S|45|Manual|A2424| | | QC| | | | 11|IMI-RF|164.1| | | 20050627153207|[CR][ETX]89[CR][LF]
R: [ACK]
S: [STX]7S|46|Manual|A2424| | | QC| | | | 11|RBC-O|2.21| | | 20050627153207|[CR][ETX]03[CR][LF]
R: [ACK]
S: [STX]0S|47|Manual|A2424| | | QC| | | | 11|PLT-O|66| | | 20050627153207|[CR][ETX]BF[CR][LF]
R: [ACK]
S: [STX]1S|48|Manual|A2424| | | QC| | | | 11|RBC-Y|152.5| | | 20050627153207|[CR][ETX]41[CR][LF]
...

Appendixes
4.3 Appendix C: Host codes

4.3.1 Haematology discipline
4.3.1.1 Diagnostic parameter
Haematology Code Parameter name

WBC Number of all leukocytes
CBC RBC Number of all erythrocytes
HGB Hemoglobin concentration
HCT Hematocrit value: Erythrocytes ratio of total blood volume
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
PLT Number of all platelets
RDW-CV Calculated distribution width of erythrocytes, coefficient of variation
RDW-SD Calculated distribution width of erythrocytes, standard deviation
P-LCR Platelet- Large Cell Ratio
PCT Plateletcrit
PDW Calculated distribution width of platelets
MPV Mean platelet volume
NEUT# Neutrophil Count
DIFF NEUT% Neutrophil Percent
LYMPH# Lymphocyte Count
LYMPH% Lymphocyte Percent
MONO# Monocyte Count
MONO% Monocyte Percent
EO# Eosinophil Count
EO% Eosinophil Percent
BASO# Basophil Count
BASO% Basophil Percent
IG# Immature granulocytes in #
IG% Immature granulocytes in %
HPC# Hematopoietic Progenitor Cell Count
 RET# Reticulocyte Count
RET RET% Reticulocyte Percent
RET-HE Reticulocyte Hemoglobin Equivalent
LFR Low Fluorescence Ratio
MFR Middle Fluorescence Ratio
HFR High Fluorescence Ratio
IRF Immature Reticulocyte Fraction
IPF Immature Platelet Fraction
NRBC NRBC# Nucleated RBC Count
NRBC% Nucleated RBC Percent

Appendixes

HBA1C A1a% fraction of Hemoglobin A1a in % from HbA1
A1b% fraction of Hemoglobin A1b in % from HbA1
F% fraction of fetal hemoglobin in % from Hb
LA1c% fraction of labile fraction of SA1c in % from HbA1
SA1c% Fraction of Glycohemoglobin in % from HbA1
IFCC Fraction of Glycohemoglobin in mmol/mol
A0% fraction of hemoglobin A0 in % from HbA
H-V0% ID of the hemoglobin Variant % from HbA1
HbF% fraction of fetal hemoglobin in % from Hb in Beta-Thal mode
HbA2% Fraction of hemoglobin A2 in % from Hb in Beta-Thal mode
HbD+% Variant D in % from HbA1 in Beta-Thal mode
HbS+% Variant S in % from HbA1 in Beta-Thal mode
HbC+% Variant C in % from HbA1 in Beta-Thal mode
TotalA1% Fraction of total A1 hemoglobin in % from HbA
ESR ESR Erythrocyte sedimentation rate
BF (Bodyfluid) MN# Mononuclear Cell Count
MN% Mononuclear Cell Percent
PMN# Polymorphonuclear Cell Count
PMN% Polymorphonuclear Cell Count
WBC-BF WBC Body Fluid
RBC-BF RBC Body Fluid
TC-BF# Total cell count body fluid

Appendixes
4.3.1.2 Research parameter

Research WBC-B
parameter WBC-D
NEUT%_RESEARCH
LYMPH%_RESEARC
MONO%_RESEARCH
EO%_RESEARCH
BASO%_RESEARCH
NEUT#_RESEARCH
LYMPH#_RESEARCH
MONO#_RESEARCH
EO#_RESEARCH
BASO#_RESEARCH
IG%_RESEARCH
IG#_RESEARCH
RBC-BF_RESEARCH
BASO-X
BASO-Y
DIFF-X
DIFF-Y
NRBC-X
NRBC-Y
IMI#
IMI-DC
IMI-RF
RBC-O
PLT-O
RBC-X
RBC-Y
d-RBC
d-PLT
Dw/X
Dw/Y
NEUT#&
NEUT%&
LYMPH#&
LYMPH%&
HFLC#
HFLC%
AREA#
AREA%
NRBC+W
NEUT-X
NEUT-Y
PLT-I
TC-PMN%
TC-MN%
TC-EO%
TC-HF
TC-HF%

Appendixes

Research HF-BF#
parameter HF-BF%
FRC#
FRC%
IRF-Y
HYPO-HE
HYPER-HE
MICROR
MACROR
H-IPF
IPF#
PLT-X
RBC-HE
D-HE
RET-Y
RPI
EO-BF#
EO-BF%
TNC-D
BA-D#
BA-D%
NE-SSC
NE-SFL
NE-FSC
LY-X
LY-Y
LY-Z
MO-X
MO-Y
MO-Z
NE-WX
NE-WY
NE-WZ
LY-WX
LY-WY
LY-WZ
MO-WX
MO-WY
MO-WZ
WBC-D
RBC-He
D-He (Delta-He)

Appendixes

Research UPP(RET)
parameter TNC(RET)
WBC-P
TNC-P
AREA1#(PLTF)
NE-BF#
NE-BF%
LY-BF#
LY-BF%
MO-BF#
MO-BF%
RBC-BF(Research)
3 Note:
Please check with your Sysmex representative for the
used parameters at the respective installation.

Appendixes
4.3.1.3 Services parameter

Service WNR-X
parameter WNR-Y
WNR-Z
WNR-WX
WNR-WY
NRBC-1#
NRBC-2#
NRBC-1%
NRBC-2%
HGB-BLANK
HGB-SAMPLE
R-MFV
S-RBC
S-MCV
L-RBC
L-MCV
P-MFV
WDF-X
WDF-Y
WDF-Z
WDF-WX
WDF-WY
WBC-FX(WDF)
DLT-WBCD
RBC-X
RET-X
RBC-Z
RBC-WX
RBC-WY
DLT-RBC
DLT-PLTO
Unclassified(RET)
WPC-X
WPC-Y
WPC-Z
DLT-WBCP
AREA1#(WPC)
AREA2#(WPC)
AREA3#(WPC)
WPC-GR#
WPC-LY#
WPC-MO#
WPC-LY2#
WPC-SC#
WPC-FL-H1#
WPC-FL-H2#

Appendixes

Service WPC-FL-H3#
parameter WPC-FL-L1#
WPC-LC1#
WPC-LC2#
WPC-GR-X
WPC-GR-Y
WPC-GR-Z
WPC-LY-X
WPC-LY-Y
WPC-LY-Z
WPC-MO-X
WPC-MO-Y
WPC-MO-Z
WPC-LY2-X
WPC-LY2-Z
WPC-SC-X
WPC-SC-Z
PLTF-X
PLTF-Y
PLTF-Z
RBC-X(PLTF)
RBC-Y(PLTF)
RBC-Z(PLTF)
RBC-WX(PLTF)
RBC-WY(PLTF)
DLT-PLTF
RBC-BF-I
RBC-BF-O
LY-BF1#
LY-BF2#
MO-BF1#
MO-BF2#
MO-BF3#
HF-BF1#
HF-BF2#
LY-BF1%
LY-BF2%
MO-BF1%
MO-BF2%
MO-BF3%
HF-BF1%
HF-BF2%
3 Note:

Appendixes
Disclaimer Research Parameter + Service Parameter

Parameter defined as “research parameters” (listed at table
above) and “service parameters” and which are obtained from
in vitro examination of specimens derived from the human
body used for the purpose of providing information:
 concerning a physiological or pathological state, or
 concerning a congenital abnormality, or
 to determine the safety and compatibility with potential
recipients, or
 to monitor therapeutic measures
are not officially intended by SYSMEX to be included in
patient’s reports as “reportable (diagnostic) parameters”.
If the user/licencee of the Sysmex instruments wants to use
these Research Parameter + Service Parameter in official
diagnosis for patients or in patient reports, he may do so, but
before he can use them for this purpose, it is under his own
responsibility to make a full evaluation of data, limitations,
interferences and complete risk management (ISO 14971)
after In-vitro Diagnostic Directive. (IVDD 98/79/EC, Annex VIII)
and its national transpositions in EU member states law.
4.3.1.4 Manual Differential parameter (diagnostic parameters)
Profile Code Parameter name
Sysmex DI-60 W_BL%1 Blast %

® W_PMY%1 Promyelocytes %
CellaVision
W_MY%1 Myelocytes %
DM-Series W_MMY%1 Metamyelocytes %
& Diff Pad W_BNE%1 Band Neutrophile %
W_SNE%1 Segmented Neutrophile %
Cell_Classes W_LY%1 Lymphocytes %
W_MO%1 Monocytes %
W_EO%1 Eosinophile %
W_BA%1 Basophile %
W_VLY%1 Var.Lymphocytes %
W_PC%1 Plasmacell %
1
W_OTH% Other %
W_LGLY%1 LG-Lymphocyte %
W_PLY%1 Pro-Lymphocyte %
W_IBO%1 Immature Basophile %
W_IEO%1 Immature Eosinophile %
W_HC%1 Hairy Cell %
W_SEC%1 Sezary Cell %

W_PMO%1 Pro-Monocyte %
W_ERB%1 NRBC% %
W_SMU%1 Smudge % (excl 100/WBC)

Appendixes

W_ART%1 Artefact %
W_MEK%1 Megakaryocyte %
W_GT%1 Giant PLT %
W_TAG%1 PLT Clumps %
1
W_USRWBC1% USER WBC1 %
1
W_USRWBC2% USER WBC 2 %
W_USRWBC3%1 USER WBC 3 %
1
1
1
1
1
W_USRNWBC1%1 USER NON WBC1 %
W_USRNWBC2%1 USER NON WBC 2 %
W_DIFFCOUNT# Total number of WBC counted
Sysmex DI-60 R_CPOL Polychromasia
R_CHYP Hypochromasia
CellaVision®
R_ZANI Anisocytosis
DM-Series R_ZMIC Microcytosis
& Diff Pad R_ZMAC Macrocytosis
RBC Morphology R_SPOC Poikilocytosis
Comments R_STA Target cells
R_SSCC Schistocytosis
R_SHE Helmet cells
R_SSI Sickle cells
R_SSPC Spherocytosis
R_SELC Elliptocytosis
R_SOVC Ovalocytosis
R_STD Tear drop cells
R_SSTC Stomatocytosis
R_SACC Acanthocytosis
R_SECC Echinocytosis
R_IHJB Howell-Jolly bodies
R_IPAB Pappenheimer bodies
R_IBST Basophilic stippling
R_IPAR Parasites
R_USRRBC1 USER_RBC 1

Appendixes

Comment COMD01 Comment 1
COMD02 Comment 2
COMD03 Comment 3
COMD04 Comment 4
COMD05 Comment 5
COMD06 Comment 6
COMD07 Comment 7
COMD08 Comment 8
COMD09 Comment 9
COMD10 Comment 10
COMD11 Comment 11
COMD12 Comment 12
1 All parameters listed for Sysmex DI-60, CellaVision ® DM-Series & Diff Pad, Cell_Classes are
also available in # count.
3 Note:

Appendixes
4.3.1.5 Body Fluid Differential (diagnostic parameters)
Sysmex DI-60 BF_NE%2 Neutrophile %

® BF_LY%2 Lymphocytes %
CellaVision
BF_EO%2 Eosinophile %
DM-Series BF_MAC%2 Macrophage %
& Diff Pad BF_SMU%2 Smudge %
BF_ART%2 Artefact %
BF_OTH%2 Other %
Cell_Classes BF_USRWBC1%2 USER BF WBC1 %
BF_USRWBC2%2 USER BF WBC 2 %
BF_USRNWBC1%2 USER BF NON WBC 1 %
2All parameters listed for Sysmex DI-60, CellaVision ® DM-Series & Diff Pad, Cell_Classes are also available in # count.
3 Note:

Appendixes
4.3.2 Urinalysis section
Urinalysis Code Parameter name

 RBC-U Red blood cells
Urinalysis WBC-U White blood cells
EC Epithelial cells
BACT Bacteria
CAST Casts
PATHCAST(*) Pathological Casts
SRC(*) Small round cells
SPERM(*) Spermatozoas
XTAL(*) Crystals
MUCUS(*) Mucus
COND(*) Conductivity (urine conductivity)
YLC(*) Yeast like cells

RBC-U-BF Red blood cells in body fluid
Urinalysis
WBC-U-BF White blood cells in body fluid
BF mode
TNC-U-BF Total nucleated cells in body fluid

 S_FSC
Extra QC-Data S_FSCW
S_FLH
S_FLL
S_FLLW
S_SSC
B_FSC
B_FSCW
B_FLH
3 Note:

Appendixes
Disclaimer Research Parameter

Parameter marked as (*) (research parameters) and which are
obtained from in vitro examination of specimens derived from
the human body used for the purpose of providing information:
 concerning a physiological or pathological state, or
 concerning a congenital abnormality, or
 to determine the safety and compatibility with potential
recipients, or
 to monitor therapeutic measures
are not officially intended by SYSMEX to be included in
patient's reports as "reportable (diagnostic) parameters".
If the user/licencee of the Sysmex instruments wants to use
these Research Parameter + Service Parameter in official
diagnosis for patients or in patient reports, he may do so, but
before he can use them for this purpose, it is under his own
responsibility to make a full evaluation of data, limitations,
interferences and complete risk management (ISO 14971)
after In-vitro Diagnostic Directive (IVDD 98/79/EC, Annex VIII)
and its national transpositions in EU member states law.

Appendixes
4.3.3 Coagulation section
Due to the fact that that the profile codes as well as the related
test names from the coagulation analyzers are customizable
we recommend you to contact the site where the analyzer will
be installed for the exact test codes and test names.
However please find below a table with the different test code
and test name which are the default manufacturer settings.
As mention these codes can be customized
3 Note:

Appendixes
4.4 Appendix D: Interpretation-Flags (IP Flags)

If there is a work area-manager connected to LIS all flags can
be customized and will not follow this table!
If a single analyzer is directly connected to LIS, these flags will
be in use. The UF-1000i/UF500i is also able to transmit up to
8 customizable additional flags.
XN-Series
UF-1000i\
XE-2100D
XE-2100L
XS-1000i/
XT-2000i
XT-4000i
Flagname
XE-2100
XE-5000
XT1800i
XS-800i
UF500i
(IP messages)
WBC_Abn_Scattergram         
NRBC_Abn_Scattergram   
Neutropenia         
Neutrophilia         
Lymphopenia         
Lymphocytosis         
Leukocytopenia         
Leukocytosis         
Monocytosis         
Eosinophilia         
Basophilia         
NRBC_Present    
IG_Present        
RBC_Abn_Distribution         
Dimorphic_Population         
Anisocytosis         
Microcytosis         
Macrocytosis         
Hypochromia         
Anemia         
Erythrocytosis         
RET_Abn_Scattergram     
Reticulocytosis     
PLT_Abn_Scattergram     
PLT_Abn_Distribution         
Thrombocytopenia         
Thrombocytosis         
Blasts?         
Immature_Gran?        
NRBC?        
Left_Shift?         
Atypical_Lympho?         
RBC_Lyse_Resistance?       
Abn_Lympho/L-Blasts?   
Abn_Lympho/Blasts?     
Blasts/Abn_Lympho? 

Appendixes
XN-Series
UF-1000i\
XE-2100D
XE-2100L
XS-1000i/
XT-2000i
XT-4000i
Flagname
XE-2100
XE-5000
XT1800i
XS-800i
UF500i
(IP messages)
Abn_Lympho?  
RBC_Agglutination?         
Turbidity/HGB_Interference?         
Iron_Deficiency?         
HGB_Defect?         
Fragments?         
PLT_Clumps?         
PLT_Clumps(S)?        
Debris high 
Discriminator error RBC/XTAL 
Discriminator error RBC/BACT 
Discriminator error RBC/YLC 
Urine conductivity abnormal 
Carry-over? 
1
Only available with the IG Master software
4.4.1 Action & Error Messages and positive flagging information
XN-Series
UF-1000i\
XE-2100D
XE-2100L
XS-1000i/
XT-2000i
XT-4000i
XE-2100
XE-5000
XT1800i
XS-800i
Flagname
UF500i
ACTION_MESSAGE_RET    
ACTION_MESSAGE_NRBC   
ACTION_MESSAGE_Delta         
ACTION_MESSAGE_DIFF        
Positive_Diff         
Positive_Morph         
Positive_Count         
Error_Func         
Error_Result         
ACTION_MESSAGE_WBC 
ACTION_MESSAGE_RBC 
ACTION_MESSAGE_Delta_WBC 
ACTION_MESSAGE_Delta_HGB 
ACTION_MESSAGE_Delta_MCV 
ACTION_MESSAGE_Delta_PLT 
ACTION_MESSAGE_Sample_Mixing 
_Failure?

Appendixes
4.5 Appendix E: Additional information for LIS
4.5.1 Info about a microscopically differential
SMEAR Info about a needed smear in addition to DIFF-Count

of the analyser
When this parameter with the result "DIFF" is sent to LIS,

Sysmex-Rules triggered an additional smear for unreliable
results. In this case we inform you that a microscopically
differential will follow and that the me-chanical differential will
not sent to LIS because it is unreliable. The parameters
BASO#, BASO%, LYMP#, LYMPH%, MONO#, MONO%,
EO#, EO%, NEUT#, NEUT%,IG' and IG% will not sent to LIS.
Please do the respective steps in your LIS to cancel those

tests internally and add the microscopically differential in your
LIS.
4.5.2 Info about sorting information
- SORT Sorting Information of a Tube-Sorter
4OBX | 1 | NM | SORT^SORT | N | ARCHIVE^ | | | | | | F^ |

201108081102 | | | TS-500^12345^1^1 |
In OBX-6 the compartment where the sample is put is

mentioned. In this example the sample is put into the archive.
The compartments are customizable. Details of the location
are mentioned in OBX-16. Refer to the description of the OBX-
Record.

Appendixes
4.5.3 Info about Comment management
The below log file example details all possibilities of comments

which can be issued by Extended IPU:
Patient Comment [STX]3C|1||Example of Patient Comment sent from
(as free Text) LIS[0Dh][ETX]8A[0Dh][0Ah
Patient Comment [STX]3OBR|1|9898989||wbc~plt~rbc~hct~mcv~mch~mchc~rdw-cv~rdw-
(as Comment Code) sd~hgb~mpv~pct~pdw~p-
lcr|||201404101616||1500||A||PC1~CKD^|201404101616|TUBE^COLL|DO
CTOR^Doctor
Name|555555|CLINIC|WARD|||201404101616|||||[0Dh][ETX]A2[0Dh][0Ah]
Sample Comment [STX]4C|1||Sample Comment Example as free text[0Dh][ETX]08[0Dh][0Ah]
(as free Text)
Sampe Comment [STX]3OBR|1|15253549||wbc~plt~rbc~hct~mcv~mch~mchc~rdw-cv~rdw-
(as Comment Code) sd~hgb~mpv~pct~pdw~p-
lcr~neut#~neut%~lymph#~lymph%~mono#~mono%~eo#~eo%~baso#~ba
so%~ig#~ig%~SMEAR|||201405021108||1500||A||^test01|201405021108|T
UBE^COLL|^||||||201405021108|||||[0Dh][ETX]28[0Dh][0Ah]
Result replacing Comment [STX]5OBX|16|CE|WBC^WBC|D|----^|10*3/µL|3.60-
(as Code) 10.80||||F^Validate|201405021148|||^^100125^02|Distributor[0Dh][ETX]8C[
0Dh][0Ah]
Result replacing Comment [STX]5OBX|16|CE|WBC^WBC|D|---- not measurable^|10*3/µL|3.60-
(as Code^Descr) 10.80||||F^Validate|201405021155|||^^100125^02|Distributor[0Dh][ETX]3C[
0Dh][0Ah]
Result Comment [STX]0OBX|32|NM|WBC^WBC|D|6.06^C|10*3/µL|3.90-
(as Code) 10.20||||F^Validate|201405021223|||XN-
20^05026^3^1|Distributor[0Dh][ETX]F3[0Dh][0Ah]
Result Comment [STX]0OBX|32|NM|WBC^WBC|D|6.06^Calculated|10*3/µL|3.90-
(As Description) 10.20||||F^Validate|201405021226|||XN-
20^05026^3^1|Distributor[0Dh][ETX]A5[0Dh][0Ah]
Result Manual Comment [STX]6C|1|^|Checked in Microscope, no Aggregates
observed.[0Dh][ETX]49[0Dh][0Ah]
Validation Comment [STX]7C|3|VALIDATION^COMMENT|AGED_SAMPLE[0Dh][ETX]BF[0Dh][0Ah
(as Code) ]
Validation Comment [STX]7C|3|VALIDATION^COMMENT|Aged sample. New sample
(as Description) suggested.[0Dh][ETX]D3[0Dh][0Ah]
Validation Comment [STX]7C|3|VALIDATION^COMMENT|AGED_SAMPLEÂged sample. New
(as Code^Descr) sample suggested.[0Dh][ETX]63[0Dh][0Ah]
Validation Manual Comment [STX]2C|6|VALIDATION^COMMENT|Example of Validation Manual
Comment. The comment is free text and can be span over several
lines.[0Dh][ETX]C2[0Dh][0Ah]
Count Pad Comment [STX]3C|7|COUNT^MORPH|MIC[0Dh][ETX]77[0Dh][0Ah]
(as Code)
Count Pad Comment [STX]3C|7|COUNT^MORPH|Sample counted in
(as Description) Microsope[0Dh][ETX]DA[0Dh][0Ah]
Count Pad Comment [STX]3C|7|COUNT^MORPH|MIC^Sample counted in
(as Code^Descr) Microsope[0Dh][ETX]11[0Dh][0Ah]
Count Pad Manual Comment [STX]4C|8|COUNT^MORPH|Example of Count Pad Manual Comment,
which may span several lines of Text.[0Dh][ETX]FD[0Dh][0Ah]
IP Flags [STX]1C|1|PLTÎP|PLT_Abn_Distribution[0Dh][ETX]CF[0Dh][0Ah]
Rules [STX]1C|5|WBC^RULE|ATYPICAL_LYMPHO_REACTIVE[0Dh][ETX]E0[0Dh][
(as Code) 0Ah]
Rules [STX]1C|5|WBC^RULE|Atypical lymphocytes? - Atypical lymphocytes
(as Description) suspect reactive[0Dh][ETX]15[0Dh][0Ah]

Rules [STX]1C|5|WBC^RULE|ATYPICAL_LYMPHO_REACTIVEÂtypical
(as Code^Descr) lymphocytes? - Atypical lymphocytes suspect
reactive[0Dh][ETX]B4[0Dh][0Ah]
Image Name [STX]5C|7|WBC^GRAPH|PNG&R&20140503&R&2014_05_03_23_10_c7c90
9c7-147f-4f50-a404-bc74734970d7_WDF.PNG[0Dh][ETX]02[0Dh][0Ah]

Appendixes
4.6 Appendix F: Main differences between SUITplus and SUIT

This section describes the main differences between SUITplus
and SUIT protocol.
The changes are marked in red
1. Header record format adaptation:
a. H-13: version
1H|^~\&|||||||||||SUITplus1.0|201201171613
2. Patient record format adaptation:

a. P-19: Suspected Diagnosis
2P|1|1000|||Test^Tester||20110805|M||||||||||D50.0^Bron
chitis||||||||||||||20110805
3. Order record format adaptations:
a. OBR-17: Ordering Physician

b. OBR-19: Requestor 1 (Clinic)
c. OBR-20: Requestor 2 (Ward)

4OBR|1|1234567891||WBC~PLT~RBC~HCT~MCV~MCH
~MCHC~HBG|||201108051521||||L|||201108051521|^|DC
ODE^DNAME||CCODE^CNAME|WCODE^WNAME|||201
108051521||||001
d. OBR-12: Action Code
4OBR|1|1234567891|||||201108051521||||C|||2011080515
21|^|DCODE^DNAME||CCODE^CNAME|WCODE^WNA
ME|||201108051521||||001
Following possible action code:

 A: Create new order or replace existing one
This action code doesn't exist anymore with SUITplus
 L: Create new order or merge with existing one
 C: Cancel the order. This is new with SUITplus
4. Result record format adaptations:
a. OBX-16: ProducersID
2OBX|1|NM|WBC^WBC|D|6.10^|10*3/µl|9.90-
28.20||||F^|201201171614|||XN-20Â1000^100125^02|
b. OBX-5: Parameter Classification

2OBX|1|NM|WBC^WBC|D|6.10^|10*3/µl|9.90-
28.20||||F^|201201171614|||XN-20Â1000^100125^02|

Appendixes
Following possible parameter classification

 D: Diagnostic
 R: Research
 S: Service
c. OBX-8: Reference Range

2OBX|1|NM|WBC^WBC|D|6.10^|10*3/µl|9.90-
28.20||||F^|201201171614|||XN-20Â1000^100125^02|
d. OBX-6: Result-Comment
Mutiple result comment management:
5OBX|3|NM|HGB^HGB|D|15.1^&~T|g/dL|14.2-21.7||||
F^Validate|201201171630|||XN-
20Â1000^100125^02|Distributor
e. OBX-10: Reagent Information
2OBX|1|NM|WBC^WBC|D|6.10^|10*3/µl|9.90-28.20||
NR^Z1234Â1000~WN^Z1234Â1000||F^|20120117163
7|||XN-20Â1000^100125^02|
Description
NR ReagentCode
Z1234 LotNo
A1000 SerialNo
5. Comment record format adaptation

C-3: Comment Source
2C|5|WBC^RULE|WBC morph positive -> Smear!
Description
WBC
RULE

Appendixes
6. “ETB”
SUITplus has no limitation in the string length. SUITplus does
not generate an [ETB] after 240 characters. SUITplus do not
uses "ETB"
5OBR|1||10000000|WBC^WBC~RBC^RBC~HGB^HGB~
HCT^HCT~MCV^MCV~MCH^MCH~MCHC^MCHC~PLT
^PLT~RDW-CV^RDW-CV~RDW-SD^RDW-
SD~MPV^MPV~P-LCR^P-
LCR~PDW^PDW~PCT^PCT~NEUT#^NEUT#~LYMPH#^
LYMPH#~MONO#^MONO#~EO#ÊO#~BASO#^BASO#
~IG#ÎG#~HFLC#^HFLC#~NEUT%^NEUT%~LYMPH%^
LYMPH%~MONO%^MONO%~EO%ÊO%~BASO%^BA
SO%~IG%ÎG%~HFLC%^HFLC%~NRBC#^NRBC#~NR
BC%^NRBC%~RET#^RET#~RET%^RET%~IRFÎRF~H
FR^HFR~LFR^LFR~MFR^MFR~RET-HE^RET-
HE~MICROR^MicroR~IPFÎPF~RPI^RPI~H-IPF^H-
IPF|S||201201020951||||||||^COLL|DOCTOR^Doctor
Name|555555|CLINIC^|WARD^|||201201020951||001|||X
N
7. SUITplus communication robustness improvements

There are situations where a network connection kept the
status established but it is lost.
 Firewall closed a connections after a certain time of idling
 Software / Computer crashed
 Switch was off / broken
 When getting 10 x no answer for an ENQ, then we will
close the connection and establish a new one
 When the online is 10 minutes idling then we have a keep
alive feature at the application layer.
See below an example:

S: [ENQ]
R: [ACK]
S: [EOT]

SUITPlus Protocol Description v4.0

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

SUITPlus Protocol Description v4.0

Uploaded by

Copyright:

Available Formats

SUITplus

Sysmex Universal Interface

Status Release version

3. Adaptation of chapter 3.5: Test result record:

4. Adaptation of chapter 3.6: Comment record

6. Adaptation of the chapter 4.2: Adding some log file

2 SUITplus interface description

SUITplus interface description 3

4 SUITplus interface description

2 SUIT Interface ................................................................8

3 Message Format ..........................................................15

4.3.1.4 Manual Differential parameter (diagnostic parameters) ............ 45

SUITplus interface description 5

June 2014 - Version 4.0

6 SUITplus interface description

SUITplus is only available with the Extended IPU solution.

This protocol is oriented on ASTM standards E1238-94 and

The connection to LIS has to be established by using a

SUITplus interface description 7

2.1 Data Link Level

2.1.1 Setting Status

Establish a logical communication line to determine the

1. The Sending side transmits [ENQ] to the Receiving side.

Sending side Receiving Sending side Receiving

8 SUITplus interface description

2. When both sides send [ENQ] ([ENQ] clash), the Slave

HOST SUIT HOST SUIT

[ENQ] 3. (1Sec.) Within 20 Sec.

When SUITplus gets 10 times no answer from host when

Keep Alive management:

SUITplus interface description 9

2.1.2 Forwarding Status

The Sending side transmits a message to the Receiving side.

Symbol Code Description

2.1.3 End Status

10 SUITplus interface description

1. In Setting Status, the Sending side sets a 15-second timer

2. In Forwarding Status, the Sending side sets a 15 seconds

2.1.5 Restricted message codes

Please find below 10 Transmission Restricted Message

SUITplus interface description 11

12 SUITplus interface description

Details about the records are described at chapter "3 Message

The logic order of records for doing a query by Extended IPU

Details about the records are described at chapter "3 Message

QC-Results are sent to LIS by using S-Records.Details about

SUITplus Com. Direction HOST

Patient results are sent to LIS by using OBX-Records and C-

Details about the records are described at chapter "3 Message

SUITplus interface description 13

SUITplus Com. Direction HOST

14 SUITplus interface description

3.1 Message and Record

Record Original Reference

The Record can be separated into several fields by separators.

Separator Type Symbol Description

Sub-component & Defined only in Header. Not used as separator.

Escape \ Defined only in Header. Not used as separator.

SUITplus interface description 15

3.2 Header Record

H | ^ ~ \ & | | | | | | | | | | | VER | DT<CR>

16 SUITplus interface description

3.3 Patient Record

SUITplus interface description 17